EF Hutton initiated coverage of Ocean Biomedical with a Buy rating and $10 price target.Ocean Biomedical has an impressive but under-the-radar team with a differentiated portfolio, the analyst tells investors in a research note. Now that the de-SPAC transaction with Aesther Healthcare Acquisition Corporation has closed, Ocean’s management team can set about its business developing its assets as well as identifying new ones, EF Hutton says.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCEA:
- Ocean Biomedical More than Doubles after Presenting Research Data
- Ocean Biomedical shares research data on anti-tumor pathway discoveries
- Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder
- Ocean Biomedical announces award of new patent to Scientific co-founder Kurtis
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target
